BioSpace News Archive

Total revenue of $46 million, compared to $28 million in Q2 2021 Four program starts in the quarter bringing cumulative total to 88, up 47% from Q2 2021 Net loss of per share on a basic and diluted basis compared to per share in Q2 2021

CONMED Corporation announced that it has completed its previously announced acquisition of privately-held Biorez, Inc.

Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2022.

Mirum Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $80.0 million of shares of its common stock.

The National Institute for Innovation in Manufacturing Biopharmaceuticals is pleased to announce approximately $15.8M in planned project activities through the Institute’s Project Call 5.2 for 14 new projects in technology and workforce development that will help to address key opportunities for innovation in the biopharmaceutical industry.

BioMarker Strategies announced that the journal CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS has published a manuscript by the Company’s scientists entitled “Functional Profiling of Head and Neck/Esophageal Squamous Cell Carcinoma to Predict Cetuximab Response”.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported financial results for the second quarter of 2022.

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the second quarter ended June 30, 2022 and highlighted recent corporate accomplishments.

Surgalign Holdings, Inc., a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, announced financial results for its 2022 second quarter ended June 30, 2022.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the quarter ended June 30, 2022.